Document Classification

Section Type: RESULTS

Text: Lixisenatide significantly improved mean HbA (1c) from a baseline of 7. 55 % (59. 0 mmol/mol) ; respective mean reductions for 5, 10, 20 and 30 microg doses were 0. 47, 0. 50, 0. 69 and 0. 76 % (5. 1, 5. 5, 7. 5 and 8. 3 mmol/mol), on once-daily and 0. 65, 0. 78, 0. 75 and 0. 87 % (7. 1, 8. 5, 8. 2 and 9. 5 mmol/mol) on twice-daily administrations vs. 0. 18 % (2. 0 mmol/mol) with placebo (all P < 0. 01 vs. placebo).